Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 27386350)

Published in Springerplus on June 27, 2016

Authors

Tatsuya Watanabe¹, Mamoru Narukawa²

Author Affiliations

1: Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641 Japan ; Department of Research, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
2: Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641 Japan.

Articles cited by this ↗

Under-reporting of adverse drug reactions : a systematic review. Drug Saf (2006) 6.69

Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf (2009) 3.74

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess (2011) 2.71

Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf (2004) 1.72

Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance. Drug Saf (2013) 1.13

Under-reporting of infectious gastrointestinal illness in British Columbia, Canada: who is counted in provincial communicable disease statistics? Epidemiol Infect (2007) 1.10

Adverse drug events: identification and attribution. Drug Intell Clin Pharm (1987) 0.86